Endocannabinoid concentrations in major depression: effects of childhood maltreatment and relation to hippocampal volume.
Humans
Depressive Disorder, Major
/ diagnostic imaging
Hippocampus
/ pathology
Endocannabinoids
/ blood
Female
Male
Adult
Arachidonic Acids
/ blood
Polyunsaturated Alkamides
Middle Aged
Glycerides
/ blood
Magnetic Resonance Imaging
Adult Survivors of Child Abuse
Canada
Organ Size
Case-Control Studies
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
12 Oct 2024
12 Oct 2024
Historique:
received:
29
07
2024
accepted:
02
10
2024
revised:
26
09
2024
medline:
12
10
2024
pubmed:
12
10
2024
entrez:
11
10
2024
Statut:
epublish
Résumé
Evidence from preclinical animal models suggests that the stress-buffering function of the endocannabinoid (eCB) system may help protect against stress-related reductions in hippocampal volume, as is documented in major depressive disorder (MDD). However, stress exposure may also lead to dysregulation of this system. Thus, pathways from marked stress histories, such as childhood maltreatment (CM), to smaller hippocampal volumes and MDD in humans may depend on dysregulated versus intact eCB functioning. We examined whether the relation between MDD and peripheral eCB concentrations would vary as a function of CM history. Further, we examined whether eCBs moderate the relation of CM/MDD and hippocampal volume. Ninety-one adults with MDD and 62 healthy comparison participants (HCs) were recruited for a study from the Canadian Biomarker Integration Network in Depression program (CAN-BIND-04). The eCBs, anandamide (AEA) and 2-arachidonylglycerol (2-AG), were assessed from blood plasma. Severe CM history was assessed retrospectively via contextual interview. MDD was associated with eCBs, though not all associations were moderated by CM or in the direction expected. Specifically, MDD was associated with higher AEA compared to HCs regardless of CM history, a difference that could be attributed to psychotropic medications. MDD was also associated with higher 2-AG, but only for participants with CM. Consistent with hypotheses, we found lower left hippocampal volume in participants with versus without CM, but only for those with lower AEA, and not moderate or high AEA. Our study presents the first evidence in humans implicating eCBs in stress-related mechanisms involving reduced hippocampal volume in MDD.
Identifiants
pubmed: 39394160
doi: 10.1038/s41398-024-03151-z
pii: 10.1038/s41398-024-03151-z
doi:
Substances chimiques
Endocannabinoids
0
Arachidonic Acids
0
glyceryl 2-arachidonate
8D239QDW64
Polyunsaturated Alkamides
0
anandamide
UR5G69TJKH
Glycerides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
431Informations de copyright
© 2024. The Author(s).
Références
Kessler RC, Wai TC, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617–27.
pubmed: 15939839
pmcid: 2847357
doi: 10.1001/archpsyc.62.6.617
World Health Organization. Depression and other common mental disorders: global health estimates. World Health Organ. 2017;1:24.
NIMH. Research Domain Criteria (RDoC). https://www.nimh.nih.gov/research/research-funded-by-nimh/rdoc/about-rdoc.shtml .
Hammen C. Stress and depression. Annu Rev Clin Psychol. 2005;1:293–319.
pubmed: 17716090
doi: 10.1146/annurev.clinpsy.1.102803.143938
Harkness KL, Monroe SM. The assessment and measurement of adult life stress: basic premises, operational principles, and design requirements. J Abnorm Psychol. 2016;125:727–45.
pubmed: 27254487
doi: 10.1037/abn0000178
Li M, D’Arcy C, Meng X. Maltreatment in childhood substantially increases the risk of adult depression and anxiety in prospective cohort studies: systematic review, meta-analysis, and proportional attributable fractions. Psychol Med. 2016;46:717–30.
pubmed: 26708271
doi: 10.1017/S0033291715002743
Kessler RC, Davis CG, Kendler KS. Childhood adversity and adult psychiatric disorder in the US National Comorbidity Survey. Psychol Med. 1997;27:1101–19.
pubmed: 9300515
doi: 10.1017/S0033291797005588
Belleau EL, Treadway MT, Pizzagalli DA. The impact of stress and major depressive disorder on hippocampal and medial prefrontal cortex morphology. Biol Psychiatry. 2019;85:443–53.
pubmed: 30470559
doi: 10.1016/j.biopsych.2018.09.031
Opel N, Redlich R, Zwanzger P, Grotegerd D, Arolt V, Heindel W, et al. Hippocampal atrophy in major depression: a function of childhood maltreatment rather than diagnosis. Neuropsychopharmacology. 2014;39:2723–31.
pubmed: 24924799
pmcid: 4200502
doi: 10.1038/npp.2014.145
Reggio PH. Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. Curr Med Chem. 2010;17:1468–86.
pubmed: 20166921
pmcid: 4120766
doi: 10.2174/092986710790980005
Lutz B, Marsicano G, Maldonado R, Hillard CJ. The endocannabinoid system in guarding against fear, anxiety and stress. Nat Rev Neurosci. 2015;16:705–18.
pubmed: 26585799
pmcid: 5871913
doi: 10.1038/nrn4036
Morena M, Patel S, Bains JS, Hill MN. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology. 2016;41:80–102.
pubmed: 26068727
doi: 10.1038/npp.2015.166
Petrie GN, Balsevich G, Füzesi T, Aukema RJ, Driever WPF, van der Stelt M, et al. Disruption of tonic endocannabinoid signalling triggers cellular, behavioural and neuroendocrine responses consistent with a stress response. Br J Pharmacol. 2023;180:3146–59.
pubmed: 37482931
doi: 10.1111/bph.16198
Mayo LM, Rabinak CA, Hill MN, Heilig M. Targeting the endocannabinoid system in the treatment of posttraumatic stress disorder: a promising case of preclinical-clinical translation? Biol Psychiatry. 2022;91:262–72.
pubmed: 34598785
doi: 10.1016/j.biopsych.2021.07.019
Mayo LM, Asratian A, Lindé J, Holm L, Nätt D, Augier G, et al. Protective effects of elevated anandamide on stress and fear-related behaviors: translational evidence from humans and mice. Mol Psychiatry. 2018;25:993–1005.
pubmed: 30120421
doi: 10.1038/s41380-018-0215-1
Mayo LM, Asratian A, Lindé J, Morena M, Haataja R, Hammar V, et al. Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: a randomized, controlled experimental medicine trial. Biol Psychiatry. 2020;87:538–47.
pubmed: 31590924
doi: 10.1016/j.biopsych.2019.07.034
Hill MN, Kambo JS, Sun JC, Gorzalka BB, Galea LAM. Endocannabinoids modulate stress-induced suppression of hippocampal cell proliferation and activation of defensive behaviours. Eur J Neurosci. 2006;24:1845–9.
pubmed: 17067290
doi: 10.1111/j.1460-9568.2006.05061.x
Hill MN, Lee FS. Endocannabinoids and stress resilience: is deficiency sufficient to promote vulnerability? Biol Psychiatry. 2016;79:792–3.
pubmed: 27130852
pmcid: 5086031
doi: 10.1016/j.biopsych.2016.03.2099
Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ, et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology. 2005;30:508–15.
pubmed: 15525997
doi: 10.1038/sj.npp.1300601
Hill MN, Eiland L, Lee TTY, Hillard CJ, McEwen BS. Early life stress alters the developmental trajectory of corticolimbic endocannabinoid signaling in male rats. Neuropharmacology. 2019;146:154–62.
pubmed: 30496752
doi: 10.1016/j.neuropharm.2018.11.036
Meyer HC, Lee FS, Gee DG. The role of the endocannabinoid system and genetic variation in adolescent brain development. Neuropsychopharmacol. 2018;43:21–33.
doi: 10.1038/npp.2017.143
Hill MN, Miller GE, Ho WSV, Gorzalka BB, Hillard CJ. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry. 2008;41:48–53.
pubmed: 18311684
pmcid: 3422568
doi: 10.1055/s-2007-993211
Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology. 2009;34:1257–62.
pubmed: 19394765
pmcid: 2716432
doi: 10.1016/j.psyneuen.2009.03.013
Koenig AM, Gao W, Umlauft M, Schury K, Reister F, Kirschbaum C, et al. Altered hair endocannabinoid levels in mothers with childhood maltreatment and their newborns. 2018. https://doi.org/10.1016/j.biopsycho.2018.03.006 .
Behnke A, Gumpp AM, Rojas R, Sänger T, Lutz-Bonengel S, Moser D, et al. Circulating inflammatory markers, cell-free mitochondrial DNA, cortisol, endocannabinoids, and N-acylethanolamines in female depressed outpatients. World J Biol Psychiatry. 2023;24:58–69.
pubmed: 35532037
doi: 10.1080/15622975.2022.2070666
Bersani G, Pacitti F, Iannitelli A, Caroti E, Quartini A, Xenos D, et al. Inverse correlation between plasma 2-arachidonoylglycerol levels and subjective severity of depression. Hum Psychopharmacol: Clin Exp. 2021;36:e2779.
doi: 10.1002/hup.2779
Ho WSV, Hill MN, Miller GE, Gorzalka BB, Hillard CJ. Serum contents of endocannabinoids are correlated with blood pressure in depressed women. Lipids Health Dis. 2012;11:32.
pubmed: 22373123
pmcid: 3334711
doi: 10.1186/1476-511X-11-32
Coccaro EF, Hill MN, Robinson L, Lee RJ. Circulating endocannabinoids and affect regulation in human subjects. Psychoneuroendocrinology. 2018;92:66–71.
pubmed: 29627714
doi: 10.1016/j.psyneuen.2018.03.009
Romero-Sanchiz P, Nogueira-Arjona R, Pastor A, Araos P, Serrano A, Boronat A, et al. Plasma concentrations of oleoylethanolamide in a primary care sample of depressed patients are increased in those treated with selective serotonin reuptake inhibitor-type antidepressants. Neuropharmacology. 2019;149:212–20.
pubmed: 30822499
doi: 10.1016/j.neuropharm.2019.02.026
Gowatch LC, Evanski JM, Ely SL, Zundel CG, Bhogal A, Carpenter C, et al. Endocannabinoids and stress-related neurospsychiatric disorders: a systematic review and meta-analysis of basal concentrations and response to acute psychosocial stress. Cannabis Cannabinoid Res. 2024. https://doi.org/10.1089/can.2023.0246 .
Perini I, Mayo LM, Capusan AJ, Paul ER, Yngve A, Kampe R, et al. Resilience to substance use disorder following childhood maltreatment: association with peripheral biomarkers of endocannabinoid function and neural indices of emotion regulation. Mol Psychiatry. 2023;28:2563–2571.
pubmed: 37041416
pmcid: 10611562
doi: 10.1038/s41380-023-02033-y
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR. American Psychiatric Association: Washington, DC; 2000.
Rohleder N, Kirschbaum C. The hypothalamic–pituitary–adrenal (HPA) axis in habitual smokers. Int J Psychophysiol. 2006;59:236–43.
pubmed: 16325948
doi: 10.1016/j.ijpsycho.2005.10.012
First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition (SCID-I/P). Biometrics Research, New York State Psychiatric Institute: New York, NY, 2002.
Grove WM, Andreasen NC, McDonald-Scott P, Keller MB, Shapiro RW. Reliability studies of psychiatric diagnosis: theory and practice. Arch Gen Psychiatry. 1981;38:408–13.
pubmed: 7212971
doi: 10.1001/archpsyc.1981.01780290042004
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.
pubmed: 444788
doi: 10.1192/bjp.134.4.382
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573–83.
pubmed: 12946886
doi: 10.1016/S0006-3223(02)01866-8
Watson D, Weber K, Assenheimer JS, Clark LA, Strauss ME, McCormick RA. Testing a tripartite model: I. Evaluating the convergent and discriminant validity of anxiety and depression symptom scales. J Abnorm Psychol. 1995;104:3–14.
pubmed: 7897050
doi: 10.1037/0021-843X.104.1.3
Zohar J, Stahl S, Moller H-J, Blier P, Kupfer D, Yamawaki S, et al. A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol. 2015;25:2318–25.
pubmed: 26527055
doi: 10.1016/j.euroneuro.2015.08.019
Scherma M, Masia P, Satta V, Fratta W, Fadda P, Tanda G. Brain activity of anandamide: a rewarding bliss? Acta Pharm Sin. 2019;40:309–23.
doi: 10.1038/s41401-018-0075-x
Bifulco A, Brown GW, Harris TO. Childhood experience of care and abuse (CECA): a retrospective interview measure. J Child Psychol Psychiatry Allied Discip. 1994;35:1419–35.
doi: 10.1111/j.1469-7610.1994.tb01284.x
Thabrew H, de Sylva S, Romans S. Evaluating childhood adversity. In: Adv Psychosom Med. Basel, Karger. Karger Publishers, 2011, 35–57.
Baldwin JR, Reuben A, Newbury JB, Danese A. Agreement between prospective and retrospective measures of childhood maltreatment: a systematic review and meta-analysis. JAMA Psychiatry. 2019;76:584–93.
pubmed: 30892562
pmcid: 6551848
doi: 10.1001/jamapsychiatry.2019.0097
Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341–55.
pubmed: 11832223
doi: 10.1016/S0896-6273(02)00569-X
Iglesias JE, Augustinack JC, Nguyen K, Player CM, Player A, Wright M, et al. A computational atlas of the hippocampal formation using ex vivo, ultra-high resolution MRI: application to adaptive segmentation of in vivo MRI. NeuroImage. 2015;115:117–37.
pubmed: 25936807
doi: 10.1016/j.neuroimage.2015.04.042
Nogovitsyn N, Muller M, Souza R, Hassel S, Arnott SR, Davis AD, et al. Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report. Neuropsychopharmacology. 2020;45:283–91.
pubmed: 31610545
doi: 10.1038/s41386-019-0542-1
Nogovitsyn N, Ballester P, Lasby M, Dunlop K, Ceniti AK, Squires S, et al. An empirical analysis of structural neuroimaging profiles in a staging model of depression. J Affect Disord. 2024;351:631–40.
pubmed: 38290583
doi: 10.1016/j.jad.2024.01.246
Dannlowski U, Stuhrmann A, Beutelmann V, Zwanzger P, Lenzen T, Grotegerd D, et al. Limbic scars: long-term consequences of childhood maltreatment revealed by functional and structural magnetic resonance imaging. Biol Psychiatry. 2012;71:286–93.
pubmed: 22112927
doi: 10.1016/j.biopsych.2011.10.021
Frodl T, Carballedo A, Hughes MM, Saleh K, Fagan A, Skokauskas N, et al. Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder. Transl Psychiatry. 2012;2:88.
doi: 10.1038/tp.2012.14
Rowe J, Poppenk J, Squires S, Mazurka R, Nogovitsyn N, Hassel S, et al. Anxious arousal predicts within-person changes in hippocampal volume in adults with a history of childhood maltreatment: a CAN-BIND4 report. J Psychopathol Clin Sci. 2023;132:797–807.
pubmed: 37843538
doi: 10.1037/abn0000864
Mazurka R, Cunningham S, Hassel S, Foster JA, Nogovitsyn N, Fiori LM, et al. Relation of hippocampal volume and SGK1 gene expression to treatment remission in major depression is moderated by childhood maltreatment: a CAN-BIND-1 report. Eur Neuropsychopharmacol. 2024;78:71–80.
pubmed: 38128154
doi: 10.1016/j.euroneuro.2023.12.003
Roddy DW, Farrell C, Doolin K, Roman E, Tozzi L, Frodl T, et al. The Hippocampus in depression: more than the sum of its parts? Advanced hippocampal substructure segmentation in depression. Biol Psychiatry. 2019;85:487–97.
pubmed: 30528746
doi: 10.1016/j.biopsych.2018.08.021
Matias I, Gonthier M-P, Petrosino S, Docimo L, Capasso R, Hoareau L, et al. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and β-cells. Br J Pharmacol. 2007;152:676–90.
pubmed: 17704823
pmcid: 2190005
doi: 10.1038/sj.bjp.0707424
Stensson N, Ghafouri N, Ernberg M, Mannerkorpi K, Kosek E, Gerdle B, et al. The relationship of endocannabinoidome lipid mediators with pain and psychological stress in women with fibromyalgia: a case-control study. J Pain. 2018;19:1318–28.
pubmed: 29885369
doi: 10.1016/j.jpain.2018.05.008
Smaga I, Bystrowska B, Gawliński D, Pomierny B, Stankowicz P, Filip M. Antidepressants and changes in concentration of endocannabinoids and N-acylethanolamines in rat brain structures. Neurotox Res. 2014;26:190–206.
pubmed: 24652522
pmcid: 4067538
doi: 10.1007/s12640-014-9465-0
Gorzalka BB, Hill MN. Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35:1575–85.
doi: 10.1016/j.pnpbp.2010.11.021
Dubreucq S, Matias I, Cardinal P, Häring M, Lutz B, Marsicano G, et al. Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice. Neuropsychopharmacol. 2012;37:1885–1900.
doi: 10.1038/npp.2012.36
Berger AL, Henricks AM, Lugo JM, Wright HR, Warrick CR, Sticht MA, et al. The lateral habenula directs coping styles under conditions of stress via recruitment of the endocannabinoid system. Biol Psychiatry. 2018;84:611–23.
pubmed: 29887035
pmcid: 6162143
doi: 10.1016/j.biopsych.2018.04.018
Pariante CM, Papadopoulos AS, Poon L, Cleare AJ, Checkley SA, English J, et al. Four days of citalopram increase suppression of cortisol secretion by prednisolone in healthy volunteers. Psychopharmacology. 2004;177:200–6.
pubmed: 15179544
doi: 10.1007/s00213-004-1925-4
Petrie GN, Balsevich G, Füzesi T, Aukema RJ, Driever WPF, van der Stelt M, et al. Disruption of tonic endocannabinoid signalling triggers cellular, behavioural and neuroendocrine responses consistent with a stress response. Br J Pharmacol. n/a. https://doi.org/10.1111/bph.16198 .
Hillard CJ. Circulating endocannabinoids: from whence do they come and where are they going? Neuropsychopharmacology. 2018;43:155–72.
pubmed: 28653665
doi: 10.1038/npp.2017.130
Hou L, Rong J, Haider A, Ogasawara D, Varlow C, Schafroth MA, et al. Positron emission tomography imaging of the endocannabinoid system: opportunities and challenges in radiotracer development. J Med Chem. 2021;64:123–49.
pubmed: 33379862
doi: 10.1021/acs.jmedchem.0c01459
Amir Hamzah K, Turner N, Nichols D, Ney LJ. Advances in targeted liquid chromatography-tandem mass spectrometry methods for endocannabinoid and N-acylethanolamine quantification in biological matrices: a systematic review. Mass Spectrometry Rev. n/a. https://doi.org/10.1002/mas.21897 .